BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Clarity Pharmaceuticals Secures Second FDA Fast Track Designation for 64Cu-SAR-bisPSMA in Prostate Cancer Imaging

Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation product...

January 27, 2025 | News

GC Cell Hosts Landmark Symposium in Indonesia to Spotlight Immuncell-LC Cancer Immunotherapy

GC Cell, a leading cell and gene therapy company, announced the successful completion of its first thought leadership symposium in Jakarta, Indonesia....

January 24, 2025 | News

GI Innovation and LaNova Medicines Join Forces for Breakthrough Pancreatic Cancer Combination Therapy

GI Innovation (KQ:358570) announced that it signed a Memorandum of Understanding (MOU) with LaNova Medicines (LaNova) for the development o...

January 23, 2025 | News

Lepu Biopharma Partners with ArriVent BioPharma for Global Development of MRG007, a Promising ADC for GI Cancers

Lepu Biopharma Co., Ltd (Stock Code: 02157.HK) announced that it has entered into an exclusive licensing agreement with ArriVent BioPharma, Inc.&...

January 23, 2025 | News

AstraZeneca and Daiichi Sankyo’s DATROWAY Secures First US Approval for HR-Positive, HER2-Negative Breast Cancer

First approval in the US for AstraZeneca and Daiichi Sankyo’s DATROWAY based on TROPION-Breast01 results showing 37% reduction in the risk of d...

January 20, 2025 | News

IMPACT Therapeutics’ Senaparib Gains NMPA Approval as First-Line Maintenance Therapy for Advanced Ovarian Cancer

IMPACT Therapeutics ("IMPACT"), a biopharmaceutical company focusing on the discovery and development of targeted anti-cancer therapeutics based on synthet...

January 17, 2025 | News

Guardant Health and ConcertAI Partner to Advance Cancer Research with Multi-Modal Real-World Data

Collaboration enables insights from ConcertAI national database of 5.5M clinical records and Guardant profiling data across 60+ tumor types Longitudinal...

January 17, 2025 | News

Guardant Health and ConcertAI Partner to Advance Cancer Research with Multi-Modal Real-World Data

Collaboration enables insights from ConcertAI national database of 5.5M clinical records and Guardant profiling data across 60+ tumor types Longitudinal...

January 17, 2025 | News

Brunei MOH and BGI Genomics Unite to Launch National Cervical Cancer Prevention Program

Brunei Ministry of Health (MOH), in partnership with Borneo Genomics Innovation (BGIB), a joint venture of BGI Genomics in Brunei, launched the Nation...

January 17, 2025 | News

Innovent Biologics Secures Breakthrough Therapy Designation for IBI343 in Advanced Pancreatic Cancer

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality me...

January 16, 2025 | News

SN BioScience Secures FDA IND Clearance for SNB-101 Phase 1b/2 Trial, Targeting Extensive Stage Small Cell Lung Cancer

SN BioScience announced that its lead asset SNB-101 has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administra...

January 13, 2025 | News

Menarini Group Partners with Insilico Medicine on AI-Discovered Oncology Asset in $550M Licensing Deal

This is the second asset Menarini Group has inlicensed from Insilico Medicine which was discovered through their generative AI platform, si...

January 13, 2025 | News

Samsung Biologics and LigaChem Biosciences Partner to Advance ADC Therapies with New Dedicated Facility

Samsung Biologics to offer ADC services at new dedicated facility Extended collaboration reflects successful partnership and expertise Samsung Biolog...

January 09, 2025 | News

I-Mab Prioritizes Lead Program Givastomig to Advance Precision Immuno-Oncology for Gastric Cancer

Givastomig: a Claudin 18.2 ("CLDN18.2") x 4-1BB bispecific antibody, will be the lead clinical program following the Company's portfolio prioritization ...

January 07, 2025 | News

Stay Connected